More research is urgently needed to determine whether the beneficial effects of obesity are dependent upon the type of immunotherapy or obesogenic diet being administered, the type and anatomic location of the tumor model in question, or the presence of obesity-associated factors such as IL-1β or other inflammatory mediators that may be expressed to varying degrees between one individual mouse or strain versus another. Here, IL1B is linked to obesity disorder.